| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?
|
J Allergy Clin Immunol
|
2010
|
2.35
|
|
2
|
ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis.
|
J Rheumatol
|
2012
|
2.14
|
|
3
|
Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.
|
Ann Rheum Dis
|
2006
|
1.95
|
|
4
|
Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
|
JAMA
|
2011
|
1.80
|
|
5
|
Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
|
Ann Rheum Dis
|
2007
|
1.55
|
|
6
|
Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel.
|
Arthritis Rheum
|
2004
|
1.34
|
|
7
|
High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score.
|
Arthritis Rheum
|
2011
|
1.30
|
|
8
|
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.
|
Rheumatology (Oxford)
|
2009
|
1.26
|
|
9
|
Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study.
|
Hum Mutat
|
2012
|
1.19
|
|
10
|
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.
|
Ann Rheum Dis
|
2012
|
1.15
|
|
11
|
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA).
|
Pediatr Rheumatol Online J
|
2012
|
1.11
|
|
12
|
Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
|
Arthritis Rheumatol
|
2014
|
1.04
|
|
13
|
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA).
|
Pediatr Rheumatol Online J
|
2012
|
1.04
|
|
14
|
Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
|
J Rheumatol
|
2011
|
0.98
|
|
15
|
Radiologic features in juvenile idiopathic arthritis: a first step in the development of a standardized assessment method.
|
Arthritis Rheum
|
2003
|
0.97
|
|
16
|
Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.
|
Ann Rheum Dis
|
2007
|
0.94
|
|
17
|
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
|
J Rheumatol
|
2011
|
0.94
|
|
18
|
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.
|
Ann Rheum Dis
|
2012
|
0.93
|
|
19
|
Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2009
|
0.92
|
|
20
|
Diagnostic workup for mixed connective tissue disease in childhood.
|
Isr Med Assoc J
|
2008
|
0.91
|
|
21
|
Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial.
|
JAMA
|
2013
|
0.90
|
|
22
|
Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis.
|
Arthritis Care Res (Hoboken)
|
2014
|
0.90
|
|
23
|
Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002.
|
Blood
|
2003
|
0.89
|
|
24
|
Clostridium difficile-associated reactive arthritis in two children.
|
Joint Bone Spine
|
2004
|
0.88
|
|
25
|
Vaccinations in paediatric rheumatology: an update on current developments.
|
Curr Rheumatol Rep
|
2015
|
0.87
|
|
26
|
Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score.
|
Arthritis Rheum
|
2005
|
0.86
|
|
27
|
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis.
|
Arthritis Res Ther
|
2013
|
0.85
|
|
28
|
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
|
Ann Rheum Dis
|
2012
|
0.85
|
|
29
|
Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2007
|
0.84
|
|
30
|
The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
|
Expert Opin Biol Ther
|
2010
|
0.84
|
|
31
|
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
|
Rheumatology (Oxford)
|
2013
|
0.84
|
|
32
|
Using registries to identify adverse events in rheumatic diseases.
|
Pediatrics
|
2013
|
0.83
|
|
33
|
Recurrent and opportunistic infections in children with primary intestinal lymphangiectasia.
|
J Pediatr Gastroenterol Nutr
|
2007
|
0.83
|
|
34
|
Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study.
|
Ann Rheum Dis
|
2011
|
0.83
|
|
35
|
Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis.
|
Rheumatology (Oxford)
|
2013
|
0.82
|
|
36
|
Survival in a recent cohort of mechanically ventilated pediatric allogeneic hematopoietic stem cell transplantation recipients.
|
Biol Blood Marrow Transplant
|
2008
|
0.81
|
|
37
|
What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
|
Arthritis Res Ther
|
2013
|
0.79
|
|
38
|
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
|
Rheumatology (Oxford)
|
2012
|
0.79
|
|
39
|
Anti-tumor necrosis factor α targets protein kinase B/c-Akt-induced resistance of effector cells to suppression in juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2013
|
0.78
|
|
40
|
Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
|
Ann Rheum Dis
|
2010
|
0.78
|
|
41
|
Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?
|
Immunotherapy
|
2014
|
0.77
|
|
42
|
Vaccination leads to an aberrant FOXP3 T-cell response in non-remitting juvenile idiopathic arthritis.
|
Ann Rheum Dis
|
2011
|
0.77
|
|
43
|
The skin in primary immunodeficiency disorders.
|
Eur J Dermatol
|
2005
|
0.77
|
|
44
|
Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis.
|
J Rheumatol
|
2013
|
0.77
|
|
45
|
Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.
|
Ann Rheum Dis
|
2013
|
0.76
|
|
46
|
Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.
|
J Rheumatol
|
2010
|
0.76
|
|
47
|
Awareness of Fabry disease among rheumatologists--current status and perspectives.
|
Clin Rheumatol
|
2011
|
0.76
|
|
48
|
Assessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists.
|
Pediatr Rheumatol Online J
|
2013
|
0.75
|
|
49
|
Dr. de Rotte, et al reply.
|
J Rheumatol
|
2013
|
0.75
|
|
50
|
Brief report: Autologous stem cell transplantation restores immune tolerance in experimental arthritis by renewal and modulation of the Teff cell compartment.
|
Arthritis Rheumatol
|
2014
|
0.75
|
|
51
|
Defining criteria for macrophage activation syndrome, a process towards early recognition and treatment.
|
J Rheumatol
|
2011
|
0.75
|
|
52
|
Do snapshot statistics fool us in MTX pharmacogenetic studies in arthritis research?
|
Rheumatology (Oxford)
|
2010
|
0.75
|
|
53
|
Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.
|
Expert Rev Clin Immunol
|
2014
|
0.75
|
|
54
|
Myelodysplastic features in Griscelli syndrome.
|
J Pediatr Hematol Oncol
|
2004
|
0.75
|